28 November 2024

Adams plc

("Adams" or the "Company")

Interim Results for the Six Months ended 30 September 2024

Chairman's Statement

Adams generated a net profit of £0.45 million for the six months ended 30 September 2024 compared to a profit of £0.29 million in the six months ended 30 September 2023.

The half year profit of £0.45 million comprises a net investment profit return of £0.55 million, less overhead costs of £0.10 million. The comparative 2023 half year profit of £0.29 million included a net investment profit return of £0.39 million, less administrative costs of £0.10 million.

There were no investment additions during the half year and during that period the Company only realised relatively minimal disposal proceeds of £0.05 million on the partial sale of one of its investment holdings.

The carrying value of the Company's equity investments at 30 September 2024 was £5.39 million represented by 7 quoted investment holdings and 4 private investments (31 March 2023: £5.31 million represented by 8 quoted investment holdings and 3 private investments). In addition, Adams holds a derivative investment asset in a private company in the form of warrants which are considered to have a nil fair value.

The Company held cash balances of £0.07 million as at 30 September 2024, compared to cash balances of £0.12 million at the previous 31 March 2024 year end.

Net assets increased to £5.43 million (equivalent to 3.72 pence per share) as at 30 September 2024 compared with £4.98 million (equivalent to 3.42 pence per share) as at 31 March 2024. The £0.45 million increase in net assets reflects the profit reported for the half year.

Business model and corporate proposals

Adams is an investing company with an investing policy under which the directors of Adams ("the Directors") sought to acquire interests in special situation investment opportunities that have an element of distress, dislocation, dysfunction or other special situation attributes and that the Directors perceive to be undervalued.

However, on 25 October 2024 the Company announced proposals to:

·    cancel the admission of the Company's shares to trading on AIM ("the Cancellation"); and

·    pursue a realisation of investments strategy and a return of capital to shareholders over the short to medium term; and

·    use the Company's existing share buyback authority to purchase shares to help enable shareholders who wish to sell their shares ahead of the Cancellation.

A circular ("the Circular") was sent to shareholders on 25 October 2024 which set out the background and reasons for the proposed Cancellation, the proposed realisation of investments and return of capital to shareholders, the initiation by the Company to use its existing share buyback authority and to explain the consequences of the Cancellation and provide reasons why the Directors unanimously consider the Cancellation to be in the best interests of the Company and its Shareholders as a whole.

The Circular included notice of an Extraordinary General Meeting ("the EGM") convened for 4.00 p.m. on 27 November 2024 to seek shareholders' approval of the Cancellation and also to amend the Company's Articles in order to facilitate the return of capital to shareholders process.

Cancellation of the Company's shares to trading on AIM

The Directors concluded, after a period of review to evaluate the benefits and drawbacks to retaining the Company's share listing on AIM and also in consultation with the Company's 94% major shareholder, Richard Griffiths, that it is in the best interests of the Company and its shareholders to seek shareholder approval for the Cancellation.

Further details of the background to and reasons for the Cancellation are set out below:

·    there is limited liquidity in the Company's shares and, as a result, the Directors believe that continued admission to trading on AIM no longer sufficiently provides the Company with the advantage of providing wider or more cost-effective access to capital in the medium to longer-term;

·    as a result of the limited liquidity in the shares highlighted above, the listing on AIM does not necessarily offer investors the opportunity to trade in meaningful volumes or with frequency within an active market. With low trading volumes, the Company's share price can move up or down significantly following trades of small volumes of shares; and

·    the considerable cost, management time and the legal and regulatory burden associated with maintaining the listing on AIM are disproportionate to the benefits to the Company given that the continued listing is unlikely to provide the Company with significantly wider or more cost-effective access to capital.

The resolution to approve the Cancellation was passed by shareholders at the EGM on 27 November 2024 and the Cancellation will now become effective at 7.00 a.m. on 5 December 2024.

Proposed realisation of investments and return of capital to shareholders

The Directors believe that UK small-cap public markets have changed significantly over the last few years with a continuing deterioration in liquidity and declining access to cost-effective growth capital. Many of the small-cap listed companies included in the Company's investment portfolio are, therefore, also in the situation where their current public market valuations do not reflect their underlying potential and there are no indications that these markets are expected to recover in the foreseeable future.

As a result, the Directors consider that the Company's strategy, with a focus to invest in the small to middle market capitalisation sectors of the UK or Europe, is no longer sufficiently attractive. In addition, the Company only has a small capital base with total balance sheet net assets of £5.43 million as at 30 September 2024 and which severely limits the alternative investment strategy options available to it. The Directors have, therefore, concluded that the Company should not make any further investments and instead should pursue an orderly realisation of existing investments and return of capital to Shareholders over the short to medium term, following which it is expected that the Company will be voluntarily wound up or subject to an administrative dissolution pursuant to the Isle of Man Companies Act 2006 ("the Companies Act").

Use by the Company of its existing share buyback authority

The Directors are aware that there is very little liquidity in the Company's shares and that shareholders who wished to sell their shares ahead of the Cancellation may have difficulty in finding buyers. The Directors agreed, therefore, that the Company will use its existing share buyback authority to make on-market purchases of its shares at a price of 4.00 pence per share ahead the Cancellation. The Directors are not making any recommendation as to whether or not shareholders should sell their shares.

Between the announcement on 25 October 2024 of the above proposal to make on-market purchases of its shares at a price of 4.00 pence per share and 26 November 2024, the Company purchased a total of 35,035 shares at a cost of £1,451. The last day of dealings in the Company's shares on AIM will be 4 December 2024.

Investment Portfolio

The portfolio investments held by the Company at 30 September 2024 included the following significant holdings, each representing at least 5% of the net asset value of the Company at that date:

NIOX Group Plc is an AIM listed global medical device company focused on point of care asthma diagnosis and management. The shareholding of Adams at 30 September 2024 was, and continues to be, 0.33 per cent. of the Niox shares in issue.

Telit IOT Solutions Limited is a private company and a global leader in Internet of Things (IoT) enablement, with an extensive portfolio of wireless connectivity modules, software platforms and global IoT connectivity services. At 30 September 2024, the investment holding by Adams in Telit represents 0.34 per cent. of Telit's issued share capital at that date.

Griffin Mining Limited is an AIM listed mining and investment company that has been the leader in foreign investment in mining in China having been engaged in developing the Caijiaying zinc and gold project since 1997. The shareholding of Adams in Griffin at 30 September 2024 was, and continues to be, 0.26 per cent. of the Griffin shares in issue.

Oxehealth Limited is a private company and an industry leader in vision-based patient monitoring and management systems. At 30 September 2024, the investment holding by Adams in Oxehealth was, and continues to be, 2.07 per cent. of Oxehealth's issued share capital at that date.

Seeing Machines Limited is an AIM listed industry leader in advanced computer vision technologies. The shareholding of Adams in Seeing Machines at 30 September 2024 was, and continues to be, 0.31 per cent. of the Seeing Machines shares in issue.

C4X Discovery Holdings Plc is a private pioneering drug discovery company combining its enhanced DNA-based target identification and candidate molecule design capabilities to efficiently deliver world‑leading medicines which are developed by licensing partners. The shareholding of Adams in C4XD at 30 September 2024 was, and continues to be, 1.98 per cent. of the C4XD shares in issue.

Pulsar Group Plc is an AIM listed London based technology innovator delivering Artificial Intelligence / AI Software-as-a-Service solutions for the global marketing and communications industries. The shareholding of Adams in Pulsar at 30 September 2024 was, and continues to be, 0.52 per cent. of the Pulsar voting shares in issue.

NCC Group Plc is a FTSE All-Share listed global tech-enabled cyber and software resilience business operating across multiple sectors, geographies and technologies. The shareholding of Adams in NCC at 30 September 2024 was, and continues to be, 0.06 per cent. of the NCC shares in issue.

In addition to the above investments, at 30 September 2024 Adams held 2 other quoted holdings, together with 1 other private company holding. The 2 quoted holdings comprise Cirata Plc and Euromax Resources Ltd. Ciratais a data activation company that enables organisations to move large datasets to the cloud at massive scale in order to activate all their data for AI, machine learning and analytics on modern cloud data platforms. Euromax is a Canadian development company listed on the Toronto Stock Exchange and focused on building and operating the Ilovica-Shtuka copper and gold project in Macedonia. The private company holding comprises Source Bioscience International Ltd which is an international provider of state-of-the art clinical diagnostics and analytical testing services.

Outlook

Your Directors intend to pursue an orderly realisation of existing investments and a return of capital to shareholders.

The Company had net assets of £5.43 million at 30 September 2024 and this included equity investments with a carrying value of £5.39 million represented by 7 quoted investment holdings valued at £3.16 million and 4 private unquoted investments valued at £2.23 million.

Whilst an orderly realisation of the 7 quoted investment holdings should be achievable in the short term, this is likely to take longer for the 4 private unquoted investments. 

The return of capital to shareholders is expected to be by way of one or more capital distributions as and when funds permit but there can be no certainty on the timing or monetary amounts of such distributions. The capital distributions will have the effect of reducing the capital and reserves of the Company and which reduction is permitted under section 58 of the Companies Act.

The Directors hope that the total value of such distributions will be not less than the Company's 3.72 pence net asset value per share at the 30 September 2024, but there can be no certainty that the total value of such distributions will not be materially less than or be materially greater than 3.72 pence per share.

In the meantime, the quoted market value of some of our listed investments have declined considerably since 30 September 2024 such that the Company's net assets are now estimated to amount to approximately £4.87 million, equivalent to 3.41 pence per share, and with a resultant year to date result reduced to a loss of £13,000 versus the profit of £450,000 reported for the first half of the year.

Michael Bretherton

Chairman

28 November 2024

Certain information contained in this announcement would have been deemed inside information for the purposes of UK Market Abuse Regulation until the release of this announcement.

The Directors of the Company take responsibility for this announcement.

Enquiries:

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.